Brief: AB Science Received First Authorization To Resume Patient Enrollment In Phase 3 Study Of Masitinib In Amyotrophic Lateral Sclerosis (ALS)

AB Science SA

23/08/2021 18:53

Aug 23 (Reuters) - AB Science SA  ABS.PA :
    * AB SCIENCE - IT HAS RECEIVED FIRST AUTHORIZATION TO RESUME
PATIENT  ENROLLLMENT IN PHASE 3 STUDY OF MASITINIB IN
AMYOTROPHIC LATERAL SCLEROSIS (ALS)
    * AB SCIENCE- AUTHORIZATION FROM NATIONAL COMPETENT
AUTHORITY
FOLLOWS SUBMISSION OF AMENDED PROTOCOL FOR AB19001 STUDY
    * AB SCIENCE-  FIRST AUTHORIZATION COMES FROM A EUROPEAN
NATIONAL
AGENCY, NAMELY NORWAY
    * AB SCIENCE-  AB SCIENCE EXPECTS TO BE ABLE TO
PROGRESSIVELY
RESUME GLOBAL ENROLLMENT DURING THE MONTH OF SEPTEMBER
    * AB SCIENCE - VOLUNTARY DECISION TO SUSPEND ENROLLMENT OF
NEW
PATIENTS WILL HAVE RESULTED IN 3 MONTHS  BREAK IN ENROLLMENT
SCHEDULE OF STUDY

Source text for Eikon:  ID: 
Further company coverage:  ABS.PA 

 ((Reuters.Briefs@thomsonreuters.com;))